City Therapeutics plans $158 million IPO as Iambic eyes $135 million Nasdaq debut
read at Endpoints ↗DealNeutral
City Therapeutics, an RNAi startup founded by former Alnylam Pharmaceuticals executives, announced plans for an initial public offering targeting roughly $158 million. The company intends to sell about 9.72 million shares at $17 each.
Iambic, another biotech firm, is preparing a Nasdaq debut aimed at raising approximately $135 million.
The news briefing also noted activity from other biotech companies such as Alchemist Capital, Newron Pharmaceuticals, Life Biosciences, Onyx Bio and Tecentriq, though no further details were provided.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “City Therapeutics targets $158M IPO; Iambic seeks $135M Nasdaq debut”
read at Endpoints ↗79 words · retrieved 2h ago
comments(0)
5-min edit window · permanent after that